Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial. Issue 2 (10th November 2022)

• Record Type: Journal Article
• Authors: Mashayekhi, Mona; Beckman, Joshua A.; Nian, Hui; Garner, Erica M.; Mayfield, Dustin; Devin, Jessica K.; Koethe, John R.; Brown, Jonathan D.; Cahill, Katherine N.; Yu, Chang; Silver, Heidi; Niswender, Kevin; Luther, James M.; Brown, Nancy J.
• Is Part Of: Diabetes, obesity & metabolism. Volume 25:Issue 2(2023)
• Page Start: 570
• Page End: 580
• Publication Date: 2022-11-10
• Subjects: cardiovascular disease -- dietary intervention -- DPP4 inhibitor -- GLP‐1 receptor agonist -- incretin physiology -- randomized trial; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14903
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: Aim: To test the hypothesis that glucagon‐like peptide‐1 receptor (GLP‐1R) agonists have beneficial effects on vascular endothelial function, fibrinolysis and inflammation through weight loss‐independent mechanisms. Materials and Methods: Individuals with obesity and prediabetes were randomized to 14 weeks of the GLP‐1R agonist liraglutide, hypocaloric diet or the dipeptidyl peptidase‐4 inhibitor sitagliptin in a 2:1:1 ratio. Treatment with drug was double blind and placebo‐controlled. Measurements were made at baseline, after 2 weeks prior to significant weight loss and after 14 weeks. The primary outcomes were measures of endothelial function: flow‐mediated vasodilation (FMD), plasminogen activator inhibitor‐1 (PAI‐1) and urine albumin‐to‐creatinine ratio (UACR). Results: Eighty‐eight individuals were studied (liraglutide N = 44, diet N = 22, sitagliptin N = 22). Liraglutide and diet reduced weight, insulin resistance and PAI‐1, while sitagliptin did not. There was no significant effect of any treatment on endothelial vasodilator function measured by FMD. Post hoc subgroup analyses in individuals with baseline FMD below the median, indicative of greater endothelial dysfunction, showed an improvement in FMD by all three treatments. GLP‐1R antagonism with exendin (9‐39) increased fasting blood glucose but did not change FMD or PAI‐1. There was no effect of treatment on UACR. Finally, liraglutide, but not sitagliptin or diet, reduced the chemokine monocyte chemoattractant protein‐1 (MCP‐1). Conclusion: Liraglutide and diet reduce weight, insulin resistance and PAI‐1. Liraglutide, sitagliptin and diet do not change FMD in obese individuals with prediabetes with normal endothelial function. Liraglutide alone lowers the pro‐inflammatory and pro‐atherosclerotic chemokine MCP‐1, indicating that this beneficial effect is independent of weight loss.